Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma | Zendy

Anas Younes | Zendy; Ajay K. Gopal | Zendy; Scott E. Smith | Zendy; Stephen M. Ansell | Zendy; Joseph D. Rosenblatt | Zendy; Kerry J. Savage | Zendy; Radhakrishnan Ramchandren | Zendy; Nancy L. Bartlett | Zendy; Bruce D. Cheson | Zendy; Sven de Vos | Zendy; Andres ForeroTorres | Zendy; Craig H. Moskowitz | Zendy; Joseph M. Connors | Zendy; Andreas Engert | Zendy; Emily K. Larsen | Zendy; Dana A. Kennedy | Zendy; Eric L. Sievers | Zendy; Robert Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Author(s) -

Anas Younes,

Ajay K. Gopal,

Scott E. Smith,

Stephen M. Ansell,

Joseph D. Rosenblatt,

Kerry J. Savage,

Radhakrishnan Ramchandren,

Nancy L. Bartlett,

Bruce D. Cheson,

Sven de Vos,

Andres ForeroTorres,

Craig H. Moskowitz,

Joseph M. Connors,

Andreas Engert,

Emily K. Larsen,

Dana A. Kennedy,

Eric L. Sievers,

Robert Chen

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.38.0410

Subject(s) - brentuximab vedotin , medicine , neutropenia , oncology , gastroenterology , refractory (planetary science) , phases of clinical research , adverse effect , anaplastic large cell lymphoma , surgery , cd30 , lymphoma , chemotherapy , physics , astrobiology

Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research